QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform

Rhea-AI Summary

QIAGEN (NYSE: QGEN) has expanded its QIAcuity digital PCR platform with over 100 new assays for cancer research, genetic disorders, and infectious disease surveillance. The company has launched more than 130 new assays in 2024, surpassing its goal and bringing the total to over 2,300 validated assays.

Key developments include:

• New dPCR LNA Mutation and CNV Probe Assays for cancer-relevant mutations
• dPCR Microbial DNA Detection Assays for pathogens and antibiotic resistance
• Expanded portfolio for animal diseases and plant pathogens

QIAcuity has seen strong adoption with over 2,000 placements by end of 2023. An in-vitro diagnostic version is set for launch in fall 2024, targeting clinical applications. QIAGEN is also partnering with pharma companies to develop companion diagnostics on the platform.

Positive

• Launched over 100 new assays for QIAcuity digital PCR platform, expanding research capabilities
• Exceeded 2024 goal with more than 130 new assays launched this year
• Strong adoption of QIAcuity with over 2,000 cumulative placements by end of 2023
• QIAcuity cited in over 450 publications, indicating scientific relevance
• Planned launch of in-vitro diagnostic version of QIAcuity in fall 2024, expanding into clinical testing
• Partnerships with pharma companies for companion diagnostics development on QIAcuity

Negative

• None.

Medical Research Analyst

QIAGEN's expansion of 100+ new digital PCR assays for QIAcuity is a significant development in genetic research and diagnostics. This broadens the platform's utility across various fields, including cancer research, infectious disease surveillance and genetic disorder studies. The increased assay menu, now totaling over 2,300 validated assays, enhances QIAcuity's versatility and market appeal.

The new assays, particularly the dPCR LNA Mutation and CNV Probe Assays, offer improved capabilities in detecting cancer-related genetic alterations. This could accelerate cancer research and potentially lead to more precise diagnostics. The Microbial DNA Detection Assays expand QIAcuity's reach into infectious disease research, antibiotic resistance studies and agricultural pathogen detection, addressing critical areas in public health and food security.

With over 2,000 cumulative placements and citations in 450+ publications, QIAcuity is gaining traction in the scientific community. The planned launch of an in-vitro diagnostic version in fall 2024 could open new revenue streams in clinical diagnostics, particularly in cancer monitoring and infectious disease diagnosis.

Financial Analyst

QIAGEN's expansion of its QIAcuity digital PCR offering is a strategic move to capitalize on the growing dPCR market. The introduction of 100+ new assays not only enhances the platform's versatility but also strengthens QIAGEN's competitive position in the life sciences and diagnostics sectors.

The company's ability to exceed its 2024 goal for new assay launches demonstrates strong R&D execution and market responsiveness. This expansion could drive increased adoption of QIAcuity, potentially boosting instrument sales and recurring revenue from assay purchases.

The planned launch of an in-vitro diagnostic version of QIAcuity in fall 2024 represents a significant opportunity to tap into the clinical diagnostics market, which typically offers higher margins and more stable revenue streams. Partnerships with pharmaceutical companies for companion diagnostics development further diversify QIAGEN's revenue potential and align with the trend towards personalized medicine.

While specific financial figures are not provided, the growing installed base of over 2,000 QIAcuity systems suggests a solid foundation for future consumables sales. Investors should monitor the adoption rate of these new assays and the success of the IVD launch as indicators of QIAGEN's growth in the dPCR market.

QIAGEN adds over 100 new validated QIAcuity digital PCR assays for cancer research, inherited genetic disorders, infectious disease surveillance, and other applications // QIAcuity digital PCR enables accurate and sensitive detection of low-abundance pathogens, copy number alterations and identification of rare mutations // Portfolio expansion and partnerships support increased adoption of QIAcuity across multiple application areas

Venlo, the Netherlands, Sept. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an important milestone with the launch of 100 new assays for its digital PCR (dPCR) platform QIAcuity for use in the study of cancer, inherited genetic disorders, infectious disease surveillance, and food and environmental monitoring.

These new assays are available through QIAGEN’s comprehensive GeneGlobe platform which integrates pre-designed assays with a database of more than 10,000 biological entities including genes, miRNAs, and pathways. 

QIAGEN has so far launched more than 130 new assays this year, exceeding the 2024 goal and adding to the existing total of more than 2,300 validated assays. 

“This important expansion of the menu for QIAcuity digital PCR underscores how QIAGEN is addressing the urgent needs of our customers for new solutions to help use this powerful technology in research and applied testing applications,” said Nitin Sood, Senior Vice President, Head of the Life Sciences Business Area at QIAGEN. “QIAcuity is proving to be a valuable tool for a broad range of applications requiring accurate and sensitive detection of genetic targets, driving the development of new multiplexed assay capabilities. Our efforts won’t stop here as we look to further expand QIAcuity into clinical and biopharma applications as well as new areas of Life Sciences research.”

The newly launched assays include: 

• dPCR LNA (locked nucleic acid) Mutation and dPCR CNV (copy number variation) Probe Assays are designed to investigate cancer-relevant mutations and CNVs, which means changes in the number of copies of certain DNA sequences, in genes, including mutations associated with colorectal cancer, malignant tumors of the connective and supporting tissue, so-called sarcoma, or thyroid cancer. 

• dPCR Microbial DNA Detection Assays are designed to target critical pathogens responsible for various infectious and tropical diseases, sexually transmitted and urinary tract infections as well as genes associated with antibiotic resistance. The portfolio is also being expanded to detect animal diseases and plant pathogens affecting crops.

The adoption of QIAcuity digital PCR remains strong with more than 2,000 cumulative placements at the end of 2023 and citations in over 450 publications. Key customers include pharmaceutical and biotechnology companies, academic and research organizations, diagnostic centers and forensic laboratories. 

QIAGEN's QIAcuity digital PCR platform utilizes nanoplates to disperse a sample into thousands of tiny partitions and then reads the reaction in each one simultaneously to quantify even the faintest signals from DNA and RNA. The platform integrates partitioning, thermocycling, and imaging into a streamlined multiplex workflow, reducing processing times from six hours to just two. Available in one-, four-, and eight-plate versions, the platform meets the needs of a wide range of laboratory sizes and throughput requirements.

Expanding QIAGEN’s successful dPCR portfolio into clinical testing, an in-vitro diagnostic version of QIAcuity is set for launch in the fall of 2024. The device will support applications such as diagnosing infectious diseases and monitoring cancer disease progression and treatment response with less invasive liquid biopsies. QIAGEN is also partnering with pharma companies to develop companion diagnostics on QIAcuity, making use of the platform’s sensitivity and accuracy for disease monitoring.

For more information about QIAGEN's digital PCR solutions and the new assays, please visit https://geneglobe.qiagen.com/applications/digital-pcr.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2024, QIAGEN employed more than 5,900 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Source: QIAGEN N.V.
Category: Corporate

FAQ

How many new assays has QIAGEN (QGEN) added to its QIAcuity digital PCR platform in 2024?

QIAGEN has launched more than 130 new assays for its QIAcuity digital PCR platform in 2024, exceeding its goal for the year.

What are the main applications of QIAGEN's (QGEN) new QIAcuity digital PCR assays?

The new QIAcuity assays are designed for cancer research, inherited genetic disorders, infectious disease surveillance, and food and environmental monitoring.

How many QIAcuity digital PCR systems has QIAGEN (QGEN) placed by the end of 2023?

QIAGEN reported over 2,000 cumulative placements of QIAcuity digital PCR systems by the end of 2023.

When is QIAGEN (QGEN) planning to launch the in-vitro diagnostic version of QIAcuity?

QIAGEN is set to launch the in-vitro diagnostic version of QIAcuity in the fall of 2024.